Loading…

Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke

CONTEXT The presence of antiphospholipid antibodies (aPL) has been associated with vascular occlusive events. However, the role of aPL in predicting ischemic events, particularly recurrent ischemic stroke, is controversial. OBJECTIVE To evaluate the effect of baseline aPL positivity (ie, positivity...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2004-02, Vol.291 (5), p.576-584
Main Authors: Levine, Steven R, Brey, Robin L, Tilley, Barbara C, Thompson, J L P, Sacco, Ralph L, Sciacca, Robert R, Murphy, A, Lu, Yimeng, Costigan, Teresa M, Rhine, Candi, Levin, Bruce, Triplett, Douglas A, Mohr, J P
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a369t-b4efe13f5e308fe332eef05ffeeaa35d8ba3898a319b4991d18ab08b724a4cc53
cites
container_end_page 584
container_issue 5
container_start_page 576
container_title JAMA : the journal of the American Medical Association
container_volume 291
creator Levine, Steven R
Brey, Robin L
Tilley, Barbara C
Thompson, J L P
Sacco, Ralph L
Sciacca, Robert R
Murphy, A
Lu, Yimeng
Costigan, Teresa M
Rhine, Candi
Levin, Bruce
Triplett, Douglas A
Mohr, J P
description CONTEXT The presence of antiphospholipid antibodies (aPL) has been associated with vascular occlusive events. However, the role of aPL in predicting ischemic events, particularly recurrent ischemic stroke, is controversial. OBJECTIVE To evaluate the effect of baseline aPL positivity (ie, positivity for anticardiolipin antibodies [aCL], lupus anticoagulant antibodies [LA], or both) on subsequent thrombo-occlusive events, including recurrent stroke. DESIGN, SETTING, AND PARTICIPANTS The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study (WARSS), a randomized double-blind trial (N = 2206) conducted at multiple US clinical sites from June 1993 through June 2000 and comparing adjusted-dose warfarin (target international normalized ratio, 1.4-2.8) and aspirin (325 mg/d) for prevention of recurrent stroke or death. APASS participants were 1770 (80%) WARSS participants who consented to enroll in the APASS, with usable baseline blood samples drawn prior to randomization to the WARSS and analyzed for aPL status within 90 days of index stroke by a central independent laboratory. Quality assurance was performed on approximately 10% of samples by a second independent laboratory. MAIN OUTCOME MEASURE Two-year rate of the composite end point of death from any cause, ischemic stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, and other systemic thrombo-occlusive events. The primary analysis assessed the outcome associated with aPL positivity within each WARSS treatment group separately, after risk-factor adjustment (since these aPL-positive vs aPL-negative comparisons were not randomized). RESULTS Of the 1770 APASS patients, 720 (41%) were classified as aPL-positive and 1050 (59%) as aPL-negative. There was no increased risk of thrombo-occlusive events associated with baseline aPL status in patients treated with either warfarin (relative risk [RR], 0.99; 95% confidence interval [CI], 0.75-1.31; P = .94), or aspirin (RR, 0.94; 95% CI, 0.70-1.28; P = .71). The overall event rate was 22.2% among aPL-positive and 21.8% among aPL-negative patients. There was no treatment × aPL interaction (P = .91). Patients with baseline positivity for both LA and aCL antibodies tended to have a higher event rate (31.7%) than did patients who tested negative for both antibodies (24.0%) (unadjusted RR, 1.36; 95% CI, 0.97-1.92; P = .07). Classification and regress
doi_str_mv 10.1001/jama.291.5.576
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80135252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>198136</ama_id><sourcerecordid>541575881</sourcerecordid><originalsourceid>FETCH-LOGICAL-a369t-b4efe13f5e308fe332eef05ffeeaa35d8ba3898a319b4991d18ab08b724a4cc53</originalsourceid><addsrcrecordid>eNpd0UtLxDAQAOAgiq6Pq-BFgqC3rkmTbJPjIr5AUFDxWCbplM3aNmvTCv57o64IBoaEyccwmRByyNmUM8bPl9DCNDd8qqaqmG2QCVdCZ0IZvUkmjBmdFVLLHbIb45KlxUWxTXa4LGY5E7MJqebd4FeLEFM0fuUr-pWwofIYKXQVfRxtxLcRu4E-LfrQ2pAF55ox-nekl-8pH6nv6AMM_vv84ocFvY1uga139HHowyvuk60amogH632PPF9dPl3cZHf317cX87sMxMwMmZVYIxe1QsF0jULkiDVTdY0IIFSlLQhtNAhurDSGV1yDZdoWuQTpnBJ75Oyn7qoPqeU4lK2PDpsGOgxjLHV6vspVnuDJP7gMY9-l3sqcc5HLwhQJHa_RaFusylXvW-g_yt_hJXC6BhAdNHUPnfPxzykplTAiuaMfl_7q79Zonmp8ArNLh7c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211324797</pqid></control><display><type>article</type><title>Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke</title><source>AMA Current Titles</source><creator>Levine, Steven R ; Brey, Robin L ; Tilley, Barbara C ; Thompson, J L P ; Sacco, Ralph L ; Sciacca, Robert R ; Murphy, A ; Lu, Yimeng ; Costigan, Teresa M ; Rhine, Candi ; Levin, Bruce ; Triplett, Douglas A ; Mohr, J P</creator><creatorcontrib>Levine, Steven R ; Brey, Robin L ; Tilley, Barbara C ; Thompson, J L P ; Sacco, Ralph L ; Sciacca, Robert R ; Murphy, A ; Lu, Yimeng ; Costigan, Teresa M ; Rhine, Candi ; Levin, Bruce ; Triplett, Douglas A ; Mohr, J P ; APASS Investigators</creatorcontrib><description>CONTEXT The presence of antiphospholipid antibodies (aPL) has been associated with vascular occlusive events. However, the role of aPL in predicting ischemic events, particularly recurrent ischemic stroke, is controversial. OBJECTIVE To evaluate the effect of baseline aPL positivity (ie, positivity for anticardiolipin antibodies [aCL], lupus anticoagulant antibodies [LA], or both) on subsequent thrombo-occlusive events, including recurrent stroke. DESIGN, SETTING, AND PARTICIPANTS The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study (WARSS), a randomized double-blind trial (N = 2206) conducted at multiple US clinical sites from June 1993 through June 2000 and comparing adjusted-dose warfarin (target international normalized ratio, 1.4-2.8) and aspirin (325 mg/d) for prevention of recurrent stroke or death. APASS participants were 1770 (80%) WARSS participants who consented to enroll in the APASS, with usable baseline blood samples drawn prior to randomization to the WARSS and analyzed for aPL status within 90 days of index stroke by a central independent laboratory. Quality assurance was performed on approximately 10% of samples by a second independent laboratory. MAIN OUTCOME MEASURE Two-year rate of the composite end point of death from any cause, ischemic stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, and other systemic thrombo-occlusive events. The primary analysis assessed the outcome associated with aPL positivity within each WARSS treatment group separately, after risk-factor adjustment (since these aPL-positive vs aPL-negative comparisons were not randomized). RESULTS Of the 1770 APASS patients, 720 (41%) were classified as aPL-positive and 1050 (59%) as aPL-negative. There was no increased risk of thrombo-occlusive events associated with baseline aPL status in patients treated with either warfarin (relative risk [RR], 0.99; 95% confidence interval [CI], 0.75-1.31; P = .94), or aspirin (RR, 0.94; 95% CI, 0.70-1.28; P = .71). The overall event rate was 22.2% among aPL-positive and 21.8% among aPL-negative patients. There was no treatment × aPL interaction (P = .91). Patients with baseline positivity for both LA and aCL antibodies tended to have a higher event rate (31.7%) than did patients who tested negative for both antibodies (24.0%) (unadjusted RR, 1.36; 95% CI, 0.97-1.92; P = .07). Classification and regression tree analyses did not identify a specific LA test or aCL isotype or titer that was associated with increased risk of thrombo-occlusive event. CONCLUSIONS The presence of aPL (either LA or aCL) among patients with ischemic stroke does not predict either increased risk for subsequent vascular occlusive events over 2 years or a differential response to aspirin or warfarin therapy. Routine screening for aPL in patients with ischemic stroke does not appear warranted.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.291.5.576</identifier><identifier>PMID: 14762036</identifier><identifier>CODEN: JAMAAP</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Aged ; Antibodies, Antiphospholipid - blood ; Anticoagulants - therapeutic use ; Aspirin - therapeutic use ; Biological and medical sciences ; Cohort Studies ; Drug therapy ; Female ; Heart attacks ; Humans ; Male ; Medical sciences ; Middle Aged ; Neurology ; Patients ; Platelet Aggregation Inhibitors - therapeutic use ; Proportional Hazards Models ; Prospective Studies ; Randomized Controlled Trials as Topic ; Stroke ; Stroke - immunology ; Stroke - prevention &amp; control ; Survival Analysis ; Thrombosis - immunology ; Thrombosis - prevention &amp; control ; Vascular diseases and vascular malformations of the nervous system ; Warfarin - therapeutic use</subject><ispartof>JAMA : the journal of the American Medical Association, 2004-02, Vol.291 (5), p.576-584</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright American Medical Association Feb 4, 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a369t-b4efe13f5e308fe332eef05ffeeaa35d8ba3898a319b4991d18ab08b724a4cc53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15445393$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14762036$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levine, Steven R</creatorcontrib><creatorcontrib>Brey, Robin L</creatorcontrib><creatorcontrib>Tilley, Barbara C</creatorcontrib><creatorcontrib>Thompson, J L P</creatorcontrib><creatorcontrib>Sacco, Ralph L</creatorcontrib><creatorcontrib>Sciacca, Robert R</creatorcontrib><creatorcontrib>Murphy, A</creatorcontrib><creatorcontrib>Lu, Yimeng</creatorcontrib><creatorcontrib>Costigan, Teresa M</creatorcontrib><creatorcontrib>Rhine, Candi</creatorcontrib><creatorcontrib>Levin, Bruce</creatorcontrib><creatorcontrib>Triplett, Douglas A</creatorcontrib><creatorcontrib>Mohr, J P</creatorcontrib><creatorcontrib>APASS Investigators</creatorcontrib><title>Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>CONTEXT The presence of antiphospholipid antibodies (aPL) has been associated with vascular occlusive events. However, the role of aPL in predicting ischemic events, particularly recurrent ischemic stroke, is controversial. OBJECTIVE To evaluate the effect of baseline aPL positivity (ie, positivity for anticardiolipin antibodies [aCL], lupus anticoagulant antibodies [LA], or both) on subsequent thrombo-occlusive events, including recurrent stroke. DESIGN, SETTING, AND PARTICIPANTS The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study (WARSS), a randomized double-blind trial (N = 2206) conducted at multiple US clinical sites from June 1993 through June 2000 and comparing adjusted-dose warfarin (target international normalized ratio, 1.4-2.8) and aspirin (325 mg/d) for prevention of recurrent stroke or death. APASS participants were 1770 (80%) WARSS participants who consented to enroll in the APASS, with usable baseline blood samples drawn prior to randomization to the WARSS and analyzed for aPL status within 90 days of index stroke by a central independent laboratory. Quality assurance was performed on approximately 10% of samples by a second independent laboratory. MAIN OUTCOME MEASURE Two-year rate of the composite end point of death from any cause, ischemic stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, and other systemic thrombo-occlusive events. The primary analysis assessed the outcome associated with aPL positivity within each WARSS treatment group separately, after risk-factor adjustment (since these aPL-positive vs aPL-negative comparisons were not randomized). RESULTS Of the 1770 APASS patients, 720 (41%) were classified as aPL-positive and 1050 (59%) as aPL-negative. There was no increased risk of thrombo-occlusive events associated with baseline aPL status in patients treated with either warfarin (relative risk [RR], 0.99; 95% confidence interval [CI], 0.75-1.31; P = .94), or aspirin (RR, 0.94; 95% CI, 0.70-1.28; P = .71). The overall event rate was 22.2% among aPL-positive and 21.8% among aPL-negative patients. There was no treatment × aPL interaction (P = .91). Patients with baseline positivity for both LA and aCL antibodies tended to have a higher event rate (31.7%) than did patients who tested negative for both antibodies (24.0%) (unadjusted RR, 1.36; 95% CI, 0.97-1.92; P = .07). Classification and regression tree analyses did not identify a specific LA test or aCL isotype or titer that was associated with increased risk of thrombo-occlusive event. CONCLUSIONS The presence of aPL (either LA or aCL) among patients with ischemic stroke does not predict either increased risk for subsequent vascular occlusive events over 2 years or a differential response to aspirin or warfarin therapy. Routine screening for aPL in patients with ischemic stroke does not appear warranted.</description><subject>Aged</subject><subject>Antibodies, Antiphospholipid - blood</subject><subject>Anticoagulants - therapeutic use</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Patients</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Stroke</subject><subject>Stroke - immunology</subject><subject>Stroke - prevention &amp; control</subject><subject>Survival Analysis</subject><subject>Thrombosis - immunology</subject><subject>Thrombosis - prevention &amp; control</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><subject>Warfarin - therapeutic use</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpd0UtLxDAQAOAgiq6Pq-BFgqC3rkmTbJPjIr5AUFDxWCbplM3aNmvTCv57o64IBoaEyccwmRByyNmUM8bPl9DCNDd8qqaqmG2QCVdCZ0IZvUkmjBmdFVLLHbIb45KlxUWxTXa4LGY5E7MJqebd4FeLEFM0fuUr-pWwofIYKXQVfRxtxLcRu4E-LfrQ2pAF55ox-nekl-8pH6nv6AMM_vv84ocFvY1uga139HHowyvuk60amogH632PPF9dPl3cZHf317cX87sMxMwMmZVYIxe1QsF0jULkiDVTdY0IIFSlLQhtNAhurDSGV1yDZdoWuQTpnBJ75Oyn7qoPqeU4lK2PDpsGOgxjLHV6vspVnuDJP7gMY9-l3sqcc5HLwhQJHa_RaFusylXvW-g_yt_hJXC6BhAdNHUPnfPxzykplTAiuaMfl_7q79Zonmp8ArNLh7c</recordid><startdate>20040204</startdate><enddate>20040204</enddate><creator>Levine, Steven R</creator><creator>Brey, Robin L</creator><creator>Tilley, Barbara C</creator><creator>Thompson, J L P</creator><creator>Sacco, Ralph L</creator><creator>Sciacca, Robert R</creator><creator>Murphy, A</creator><creator>Lu, Yimeng</creator><creator>Costigan, Teresa M</creator><creator>Rhine, Candi</creator><creator>Levin, Bruce</creator><creator>Triplett, Douglas A</creator><creator>Mohr, J P</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20040204</creationdate><title>Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke</title><author>Levine, Steven R ; Brey, Robin L ; Tilley, Barbara C ; Thompson, J L P ; Sacco, Ralph L ; Sciacca, Robert R ; Murphy, A ; Lu, Yimeng ; Costigan, Teresa M ; Rhine, Candi ; Levin, Bruce ; Triplett, Douglas A ; Mohr, J P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a369t-b4efe13f5e308fe332eef05ffeeaa35d8ba3898a319b4991d18ab08b724a4cc53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Antibodies, Antiphospholipid - blood</topic><topic>Anticoagulants - therapeutic use</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Patients</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Stroke</topic><topic>Stroke - immunology</topic><topic>Stroke - prevention &amp; control</topic><topic>Survival Analysis</topic><topic>Thrombosis - immunology</topic><topic>Thrombosis - prevention &amp; control</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levine, Steven R</creatorcontrib><creatorcontrib>Brey, Robin L</creatorcontrib><creatorcontrib>Tilley, Barbara C</creatorcontrib><creatorcontrib>Thompson, J L P</creatorcontrib><creatorcontrib>Sacco, Ralph L</creatorcontrib><creatorcontrib>Sciacca, Robert R</creatorcontrib><creatorcontrib>Murphy, A</creatorcontrib><creatorcontrib>Lu, Yimeng</creatorcontrib><creatorcontrib>Costigan, Teresa M</creatorcontrib><creatorcontrib>Rhine, Candi</creatorcontrib><creatorcontrib>Levin, Bruce</creatorcontrib><creatorcontrib>Triplett, Douglas A</creatorcontrib><creatorcontrib>Mohr, J P</creatorcontrib><creatorcontrib>APASS Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levine, Steven R</au><au>Brey, Robin L</au><au>Tilley, Barbara C</au><au>Thompson, J L P</au><au>Sacco, Ralph L</au><au>Sciacca, Robert R</au><au>Murphy, A</au><au>Lu, Yimeng</au><au>Costigan, Teresa M</au><au>Rhine, Candi</au><au>Levin, Bruce</au><au>Triplett, Douglas A</au><au>Mohr, J P</au><aucorp>APASS Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2004-02-04</date><risdate>2004</risdate><volume>291</volume><issue>5</issue><spage>576</spage><epage>584</epage><pages>576-584</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><coden>JAMAAP</coden><abstract>CONTEXT The presence of antiphospholipid antibodies (aPL) has been associated with vascular occlusive events. However, the role of aPL in predicting ischemic events, particularly recurrent ischemic stroke, is controversial. OBJECTIVE To evaluate the effect of baseline aPL positivity (ie, positivity for anticardiolipin antibodies [aCL], lupus anticoagulant antibodies [LA], or both) on subsequent thrombo-occlusive events, including recurrent stroke. DESIGN, SETTING, AND PARTICIPANTS The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study (WARSS), a randomized double-blind trial (N = 2206) conducted at multiple US clinical sites from June 1993 through June 2000 and comparing adjusted-dose warfarin (target international normalized ratio, 1.4-2.8) and aspirin (325 mg/d) for prevention of recurrent stroke or death. APASS participants were 1770 (80%) WARSS participants who consented to enroll in the APASS, with usable baseline blood samples drawn prior to randomization to the WARSS and analyzed for aPL status within 90 days of index stroke by a central independent laboratory. Quality assurance was performed on approximately 10% of samples by a second independent laboratory. MAIN OUTCOME MEASURE Two-year rate of the composite end point of death from any cause, ischemic stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, and other systemic thrombo-occlusive events. The primary analysis assessed the outcome associated with aPL positivity within each WARSS treatment group separately, after risk-factor adjustment (since these aPL-positive vs aPL-negative comparisons were not randomized). RESULTS Of the 1770 APASS patients, 720 (41%) were classified as aPL-positive and 1050 (59%) as aPL-negative. There was no increased risk of thrombo-occlusive events associated with baseline aPL status in patients treated with either warfarin (relative risk [RR], 0.99; 95% confidence interval [CI], 0.75-1.31; P = .94), or aspirin (RR, 0.94; 95% CI, 0.70-1.28; P = .71). The overall event rate was 22.2% among aPL-positive and 21.8% among aPL-negative patients. There was no treatment × aPL interaction (P = .91). Patients with baseline positivity for both LA and aCL antibodies tended to have a higher event rate (31.7%) than did patients who tested negative for both antibodies (24.0%) (unadjusted RR, 1.36; 95% CI, 0.97-1.92; P = .07). Classification and regression tree analyses did not identify a specific LA test or aCL isotype or titer that was associated with increased risk of thrombo-occlusive event. CONCLUSIONS The presence of aPL (either LA or aCL) among patients with ischemic stroke does not predict either increased risk for subsequent vascular occlusive events over 2 years or a differential response to aspirin or warfarin therapy. Routine screening for aPL in patients with ischemic stroke does not appear warranted.</abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>14762036</pmid><doi>10.1001/jama.291.5.576</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0098-7484
ispartof JAMA : the journal of the American Medical Association, 2004-02, Vol.291 (5), p.576-584
issn 0098-7484
1538-3598
language eng
recordid cdi_proquest_miscellaneous_80135252
source AMA Current Titles
subjects Aged
Antibodies, Antiphospholipid - blood
Anticoagulants - therapeutic use
Aspirin - therapeutic use
Biological and medical sciences
Cohort Studies
Drug therapy
Female
Heart attacks
Humans
Male
Medical sciences
Middle Aged
Neurology
Patients
Platelet Aggregation Inhibitors - therapeutic use
Proportional Hazards Models
Prospective Studies
Randomized Controlled Trials as Topic
Stroke
Stroke - immunology
Stroke - prevention & control
Survival Analysis
Thrombosis - immunology
Thrombosis - prevention & control
Vascular diseases and vascular malformations of the nervous system
Warfarin - therapeutic use
title Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A34%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiphospholipid%20Antibodies%20and%20Subsequent%20Thrombo-occlusive%20Events%20in%20Patients%20With%20Ischemic%20Stroke&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Levine,%20Steven%20R&rft.aucorp=APASS%20Investigators&rft.date=2004-02-04&rft.volume=291&rft.issue=5&rft.spage=576&rft.epage=584&rft.pages=576-584&rft.issn=0098-7484&rft.eissn=1538-3598&rft.coden=JAMAAP&rft_id=info:doi/10.1001/jama.291.5.576&rft_dat=%3Cproquest_pubme%3E541575881%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a369t-b4efe13f5e308fe332eef05ffeeaa35d8ba3898a319b4991d18ab08b724a4cc53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=211324797&rft_id=info:pmid/14762036&rfr_iscdi=true